Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Medicure

DB:NGQ1
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NGQ1
DB
CA$21M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Medicure Inc., a pharmaceutical company, engages in the development and commercialization of therapies for the cardiovascular market in the United States. The last earnings update was 133 days ago. More info.


Add to Portfolio Compare Print
  • Medicure has significant price volatility in the past 3 months.
NGQ1 Share Price and Events
7 Day Returns
12.4%
DB:NGQ1
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-71%
DB:NGQ1
-7.4%
DE Biotechs
-14.2%
DE Market
NGQ1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Medicure (NGQ1) 12.4% -17.5% -53.2% -71% -81.7% -28.5%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • NGQ1 underperformed the Biotechs industry which returned -7.4% over the past year.
  • NGQ1 underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
NGQ1
Industry
5yr Volatility vs Market

Value

 Is Medicure undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Medicure. This is due to cash flow or dividend data being unavailable. The share price is €1.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Medicure's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Medicure's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NGQ1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.18
TSXV:MPH Share Price ** TSXV (2020-04-08) in CAD CA$1.95
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Medicure.

DB:NGQ1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:MPH Share Price ÷ EPS (both in CAD)

= 1.95 ÷ -0.18

-10.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicure is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Medicure is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Medicure's expected growth come at a high price?
Raw Data
DB:NGQ1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
55.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Medicure, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Medicure's assets?
Raw Data
DB:NGQ1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$4.98
TSXV:MPH Share Price * TSXV (2020-04-08) in CAD CA$1.95
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:NGQ1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:MPH Share Price ÷ Book Value per Share (both in CAD)

= 1.95 ÷ 4.98

0.39x

* Primary Listing of Medicure.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Medicure is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Medicure's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Medicure has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Medicure expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Medicure expected to grow at an attractive rate?
  • Medicure's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • Medicure's earnings growth is expected to exceed the Germany market average.
  • Medicure's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NGQ1 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NGQ1 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 55.9%
DB:NGQ1 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 20.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NGQ1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NGQ1 Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 54 8 11 1
2022-12-31 58 11 14 1
2021-12-31 47 6 9 1
2020-12-31 37 2 3 1
2020-04-08
2019-12-31 24 -14 -4 1
DB:NGQ1 Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 25 -13 -3
2019-06-30 26 -4 -3
2019-03-31 28 -1 0
2018-12-31 29 1 4
2018-09-30 26 -3 10
2018-06-30 26 24 12
2018-03-31 26 23 12
2017-12-31 27 22 11
2017-09-30 29 30 5
2017-06-30 31 -3 5
2017-03-31 30 1 4
2016-12-31 29 6 4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Medicure's earnings are expected to grow significantly at over 20% yearly.
  • Medicure's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NGQ1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Medicure Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NGQ1 Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.67 0.67 0.67 1.00
2022-12-31 0.87 0.87 0.87 1.00
2021-12-31 0.54 0.54 0.54 1.00
2020-12-31 0.21 0.21 0.21 1.00
2020-04-08
2019-12-31 -0.29 -0.29 -0.29 1.00
DB:NGQ1 Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.18
2019-06-30 -0.18
2019-03-31 -0.01
2018-12-31 0.25
2018-09-30 0.61
2018-06-30 0.74
2018-03-31 0.74
2017-12-31 0.74
2017-09-30 0.30
2017-06-30 0.33
2017-03-31 0.26
2016-12-31 0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Medicure is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Medicure's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Medicure has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Medicure performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Medicure's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Medicure does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Medicure's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Medicure's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Medicure's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Medicure Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NGQ1 Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 24.59 -2.80 19.38 6.38
2019-06-30 26.43 -2.74 19.68 6.80
2019-03-31 27.93 -0.19 20.63 6.69
2018-12-31 29.11 3.93 19.50 6.68
2018-09-30 26.24 9.62 17.34 4.97
2018-06-30 25.93 11.73 16.23 4.37
2018-03-31 26.18 11.67 15.28 4.75
2017-12-31 27.13 11.50 14.87 5.15
2017-09-30 29.43 4.68 14.32 4.27
2017-06-30 30.60 5.12 14.47 4.48
2017-03-31 30.25 4.02 15.42 4.13
2016-12-31 29.30 3.62 15.20 3.63
2016-09-30 31.50 4.70 15.34 4.44
2016-06-30 28.71 2.35 14.01 6.07
2016-03-31 24.81 2.36 11.33 5.28
2015-12-31 22.08 1.67 10.24 4.87
2014-12-31 9.02 2.05 5.54 1.34
2014-08-31 6.43 0.21 3.71 0.74
2014-05-31 5.05 -1.93 3.62 0.69
2014-02-28 4.03 -1.61 2.88 1.20
2013-11-30 2.83 -2.77 2.77 1.58
2013-08-31 2.68 -2.78 2.53 1.71
2013-05-31 2.60 -2.57 2.32 1.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Medicure has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Medicure has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Medicure improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Medicure's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Medicure has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Medicure's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Medicure's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Medicure is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Medicure's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Medicure's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.0180837317634E+18x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Medicure Company Filings, last reported 6 months ago.

DB:NGQ1 Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 73.69 0.00 35.70
2019-06-30 74.75 0.00 45.71
2019-03-31 79.34 0.00 55.54
2018-12-31 83.59 0.00 71.89
2018-09-30 83.75 0.00 72.01
2018-06-30 85.11 0.00 69.94
2018-03-31 83.83 0.00 72.42
2017-12-31 80.71 0.00 5.26
2017-09-30 23.48 57.19 2.10
2017-06-30 35.42 61.28 4.45
2017-03-31 32.97 61.86 10.51
2016-12-31 38.28 74.20 12.27
2016-09-30 10.38 3.47 8.82
2016-06-30 6.73 3.43 7.46
2016-03-31 5.16 3.84 8.14
2015-12-31 4.46 4.24 3.57
2014-12-31 -3.91 5.73 0.49
2014-08-31 -4.32 5.46 0.50
2014-05-31 -5.88 5.46 0.23
2014-02-28 -5.10 5.55 0.04
2013-11-30 -5.27 5.59 0.01
2013-08-31 -4.80 5.45 0.01
2013-05-31 -4.33 5.33 0.13
  • Medicure's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • Medicure had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
  • Operating cash flow is negative therefore debt is not well covered.
  • Unable to confirm if the interest payments on Medicure's debt are well covered by earnings due to lack of past financial data.
X
Financial health checks
We assess Medicure's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Medicure has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Medicure's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Medicure dividends.
If you bought €2,000 of Medicure shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Medicure's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Medicure's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NGQ1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NGQ1 Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-08
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Medicure has not reported any payouts.
  • Unable to verify if Medicure's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Medicure's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Medicure has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Medicure's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Medicure afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Medicure has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Medicure's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Albert Friesen
COMPENSATION CA$315,000
AGE 72
CEO Bio

Dr. Albert David Friesen, Ph.D. serves as Chief Executive Officer and Corporate Secretary and Director at Buffalo Capital Inc. Dr. Friesen serves as Chief Executive Officer at Canam Bioresearch Inc. Dr. Friesen founded Genesys Venture Inc in 1997 and serves as its President. He serves as General Partner and Chief Executive Officer at CentreStone Ventures Inc. Dr. Friesen serves as the Chief Executive Officer at Medicure Inc. and served as its President since May 2016 until June 2019. He founded Medicure Inc., and served as its President from November 24, 1999 to July 25, 2011. As the first full time employee and President of the Winnipeg Rh Institute, Dr. Friesen oversaw the development and initial pharmaceutical approval of WinRho. He has also been instrumental in founding and the development of several health industry companies including ABI Biotechnology, Viventia Biotech Inc., (formerly Novopharm Biotech Inc.), Genesys Pharma Inc., Diamedica and Medicure Inc. and KAM Scientific Inc. Dr. Friesen's notable achievements include the establishment of several GMP production facilities for the production of human pharmaceuticals. He has also managed and initiated the research and clinical development of numerous pharmaceutical candidates, including more than 15 INDs and 2 successful NDAs. He served as the Chairman and Chief Executive Officer of Fox Resources Ltd. until May 14, 2008. Dr. Friesen co-founded Diamedica Inc., (alternate name DiaMedica Therapeutics Inc.) and served as its Chairman and Chief Executive Officer until April 8, 2008. He served as the President of Mantex Biotech Inc. Dr. Friesen co-founded Miraculins Inc. and served as its Chairman until November 1, 2011 and as its Director from June 30, 1998 to November 1, 2011. He founded the Industrial Biotechnology Association of Canada (IBAC) and served as its Chairman of its Board of Directors. Dr. Friesen co-founded Miraculins (alternate name Luminor Medical Technologies Inc.) and served as its Chairman until November 1, 2011 and also its Director from June 30, 1998 to November 1, 2011. He co-founded Kane Biotech Inc. and served as its Chairman and as its Director since May 17, 2001. Dr. Friesen serves as the Chair of the Board of Medicure Inc., Marsala Biotech Inc. and GVI Clinical Development Solutions Inc. He has been a Director of Medicure Inc. since June 10, 1998. Dr. Friesen serves on the Premier's Economic Advisory Council. He also serves on the Manitoba Innovation Council, as Co-Chairman, the Scientific Advisory Committee of the Council of Canadian Academies, the Small and Medium-sized Enterprises Advisory Board of the Canadian Ministry of Foreign Affairs and International Trade and the College of Physicians and Surgeons Council. He has been a Director at Buffalo Capital Inc. since December 14, 2016. He serves as Chairman of Waverley Pharma Inc. and has been its Director since October 25, 2017. Dr. Friesen served as a Director of Fox Resources Ltd. He served as a Director of Diamedica Inc. from January 2000 to April 8, 2008. Dr. Friesen served as a Director of Genome Prairie Inc. until May 14, 2008. He served as a Director of Diamedica Inc. from January 2000 to April 8, 2008. He served as a Director of Canada Foundation for Innovation. Dr. Friesen has an extensive network within the international biotechnology and corporate finance communities. He holds a Ph.D. in Protein Chemistry from the University of Manitoba.

CEO Compensation
  • Albert's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Albert's remuneration is lower than average for companies of similar size in Germany.
Management Team

Albert Friesen

TITLE
Founder
COMPENSATION
CA$315K
AGE
72

James Kinley

TITLE
CFO & Secretary
COMPENSATION
CA$155K
AGE
41
TENURE
8.6 yrs

Neil Owens

TITLE
President & COO
TENURE
0.8 yrs

Reuben Saba

TITLE
Vice President of Scientific & Medical Affairs
Board of Directors Tenure

Average tenure and age of the Medicure board of directors in years:

16.3
Average Tenure
75.5
Average Age
  • The average tenure for the Medicure board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Albert Friesen

TITLE
Founder
COMPENSATION
CA$315K
AGE
72

Arnold Naimark

TITLE
Independent Director
COMPENSATION
CA$16K
AGE
86
TENURE
20.2 yrs

Paul Armstrong

TITLE
Chairman of Scientific Advisory Board

Brent Fawkes

TITLE
Independent Director
COMPENSATION
CA$16K
AGE
50
TENURE
7.3 yrs

Jeffrey Weitz

TITLE
Member of Scientific Advisory Board

Pierre Theroux

TITLE
Member of Scientific Advisory Board

Morris Karmazyn

TITLE
Member of Scientific Advisory Board

Steve Hanessian

TITLE
Member of Scientific Advisory Board

Gerry McDole

TITLE
Independent Director
COMPENSATION
CA$11K
AGE
79
TENURE
16.3 yrs

Trevor Hassell

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
15. Aug 19 Buy Albert Friesen Individual 14. Aug 19 14. Aug 19 2,000 €3.20 €6,370
22. Jul 19 Buy Albert Friesen Individual 19. Jul 19 19. Jul 19 1,000 €3.14 €3,132
12. Jul 19 Buy Albert Friesen Individual 10. Jul 19 10. Jul 19 1,000 €3.19 €3,186
10. Jul 19 Buy Albert Friesen Individual 08. Jul 19 09. Jul 19 1,400 €3.36 €4,616
05. Jul 19 Buy Albert Friesen Individual 04. Jul 19 04. Jul 19 1,000 €3.33 €3,320
02. Jul 19 Buy Albert Friesen Individual 28. Jun 19 28. Jun 19 1,000 €3.24 €3,242
24. Jun 19 Buy Albert Friesen Individual 21. Jun 19 21. Jun 19 2,500 €3.34 €8,351
20. Jun 19 Buy Albert Friesen Individual 19. Jun 19 19. Jun 19 5,000 €3.34 €16,691
19. Jun 19 Buy Albert Friesen Individual 18. Jun 19 18. Jun 19 2,500 €3.40 €8,466
X
Management checks
We assess Medicure's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Medicure has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Medicure Inc., a pharmaceutical company, engages in the development and commercialization of therapies for the cardiovascular market in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia; Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure; and ReDS, a non-invasive medical device that provides measurement of lung fluid for the management of congestive heart failure. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Details
Name: Medicure Inc.
NGQ1
Exchange: DB
Founded: 1997
CA$13,483,042
10,804,013
Website: http://www.medicure.com
Address: Medicure Inc.
2-1250 Waverley Street,
Winnipeg,
Manitoba, R3T 6C6,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV MPH Common Shares TSX Venture Exchange CA CAD 23. Nov 1999
OTCPK MCUJ.F Common Shares Pink Sheets LLC US USD 23. Nov 1999
DB NGQ1 Common Shares Deutsche Boerse AG DE EUR 23. Nov 1999
Number of employees
Current staff
Staff numbers
0
Medicure employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:07
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/01/27
Last earnings filing: 2019/11/27
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.